Previous reports have suggested that certain splicing events, such those involving WT1 [41], TP53 [42], HOXA9 [43], BAALC [44], VEGF [45] or BCL-X [46], might influence disease outcome in intensively treated AML. This evidence concerns the gene BCL2L1 and acute myeloid leukemia.